ADMA Biologics Inc
NASDAQ:ADMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ADMA Biologics Inc
NASDAQ:ADMA
|
US |
|
A
|
Australian Unity Office Fund
ASX:AOF
|
AU |
|
Prakash Pipes Ltd
NSE:PPL
|
IN |
|
Charter Hall Group
ASX:CHC
|
AU |
|
D
|
Daaz Bara Lestari Tbk PT
IDX:DAAZ
|
ID |
|
W
|
WEYCO Group Inc
NASDAQ:WEYS
|
US |
|
Leon's Furniture Ltd
TSX:LNF
|
CA |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
US |
|
TomTom NV
AEX:TOM2
|
NL |
|
Emyria Ltd
ASX:EMD
|
AU |
|
N
|
Namyong Terminal PCL
SET:NYT
|
TH |
Wall Street
Price Targets
ADMA Price Targets Summary
ADMA Biologics Inc
According to Wall Street analysts, the average 1-year price target for
ADMA
is 26.18 USD
with a low forecast of 17.17 USD and a high forecast of 31.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ADMA's stock price target?
Price Target
26.18
USD
According to Wall Street analysts, the average 1-year price target for
ADMA
is 26.18 USD
with a low forecast of 17.17 USD and a high forecast of 31.5 USD.
What is ADMA Biologics Inc's Revenue forecast?
Projected CAGR
24%
For the last 14 years the
compound annual growth rate for
ADMA Biologics Inc's revenue is
59%.
The projected
CAGR
for the next 3 years is
24%.
What is ADMA Biologics Inc's Operating Income forecast?
Projected CAGR
39%
The
compound annual growth rate
of ADMA Biologics Inc's operating income for the next 3 years is
39%.
What is ADMA Biologics Inc's Net Income forecast?
Projected CAGR
37%
The
compound annual growth rate
of ADMA Biologics Inc's net income for the next 3 years is
37%.
